Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD4CAR T Cell Therapy for CMML
NCT06071624Phase 1Suspended
- Start
- Feb 2024
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD4CAR in chronic myelomonocytic leukemia (CMML). Primary endpoints: Maximum Tolerated Dose at 28 days and CMML response to CD4CAR at 6 months. Started Feb 2024; status: suspended.
02
Drugs
CD4CAR
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06071624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071624.